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Objective: SIRT1 has been proposed to be a key signaling node linking changes in energy metabolism to transcriptional adaptations. Although
SIRT1 overexpression is protective against diverse metabolic complications, especially in response to high-fat diets, studies aiming to understand
the etiology of such beneﬁts are scarce. Here, we aimed to identify the key tissues and mechanisms implicated in the beneﬁcial effects of SIRT1
on glucose homeostasis.
Methods: We have used a mouse model of moderate SIRT1 overexpression, under the control of its natural promoter, to evaluate glucose
homeostasis and thoroughly characterize how different tissues could inﬂuence insulin sensitivity.
Results: Mice with moderate overexpression of SIRT1 exhibit better glucose tolerance and insulin sensitivity even on a low fat diet. Euglycemic-
hyperinsulinemic clamps and in-depth tissue analyses revealed that enhanced insulin sensitivity was achieved through a higher brown adipose
tissue activity and was fully reversed by housing the mice at thermoneutrality. SIRT1 did not inﬂuence brown adipocyte differentiation, but
dramatically enhanced the metabolic transcriptional responses to b3-adrenergic stimuli in differentiated adipocytes.
Conclusions: Our work demonstrates that SIRT1 improves glucose homeostasis by enhancing BAT function. This is not consequent to an
alteration in the brown adipocyte differentiation process, but as a result of potentiating the response to b3-adrenergic stimuli.
 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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SIRT1 is a NADþ-dependent protein deacetylase and the best studied
mammalian homolog of the yeast enzyme Sir2, a protein with an
established capacity to inﬂuence yeast replicative lifespan [1]. In
mammals, SIRT1 targets include a constellation of transcription fac-
tors and enzymes with key roles in mitochondrial biogenesis, lipid
catabolism, cholesterol homeostasis and gluconeogenesis [1]. Studies
using SIRT1 activating compounds (STACs) in mammals have high-
lighted how SIRT1 might have pleiotropic metabolic beneﬁts. Dietary
supplementation with STACs led to increased mitochondrial biogen-
esis in diverse mouse tissues, including skeletal muscle and brown
adipose tissue (BAT), which in turn protected against high-fat diet
(HFD)-induced obesity and many of its metabolic comorbidities [2].
The speciﬁcity of these compounds, however, has been called into
question and is still unclear [3]. To overcome this problem, transgenic
mouse models with a moderate SIRT1 overexpression were gener-
ated. In them, a single copy of a large genomic construct (174 kb)
containing the entire Sirt1 gene in its natural genomic context was
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While similar to wild-type (WT) mice when fed low fat diets (LFD),
SIRT1Tg/ mice were protected against HFD-induced insulin resis-
tance, despite similar body weight gain [4]. These observations were
conﬁrmed in an independent SIRT1 overexpressing mouse line
(SirBACO) generated by the Accili lab [5]. In light of the above results,
we reasoned that the generation of a homozygous transgenic mouse
(SIRT1Tg/Tg) might lead to a more marked phenotype, likely closer to
that observed with STACs. Here, we describe how SIRT1Tg/Tg mice
display enhanced energy expenditure (EE), glucose tolerance and
insulin sensitivity even when fed an LFD. We demonstrate that this
phenotype stems from a higher BAT activity and that SIRT1Tg/Tg mice
do not show major muscle or liver functional changes on LFD. Using
immortalized brown adipocytes from SIRT1 transgenic mice we
further demonstrate that the effects of SIRT1 on BAT biology do not
derive from differences in the brown adipocyte differentiation process,
but from a higher response to b3-adrenergic stimuli. Altogether, our
work illustrates how SIRT1 gain-of-function can improve insulin
sensitivity by acting as a gauge for the BAT response to b3-adrenergic
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2. MATERIAL AND METHODS
2.1. Animal care
The SIRT1 transgenic model has already been described in Ref. [4]. In
contrast to that publication, we used homozygote transgenic male
mice SIRT1Tg/Tg which had been backcrossed to C57Bl/6N back-
ground. Unless otherwise speciﬁed, mice were kept in a standard
temperature- and humidity-controlled environment with a 12:12-h
lightedark cycle. Mice had nesting material and ad libitum access
to water and commercial LFD or HFD (D12450J and D12492,
respectively, from Research Diets Inc.). All animal experiments were
carried according to national Swiss and EU ethical guidelines and
approved by the local animal experimentation committee under
licenses 2519 and 2519.1-3. For thermoneutrality studies, mice were
housed in temperature controlled cabinets at 30 C.
2.2. Animal phenotyping
All clinical tests were carried out according to standard operational
procedures (SOPs) established and validated within the Eumorphia
program (http://empress.har.mrc.ac.uk/) [6]. Mice were weighed and
the food consumption was measured each week on the same day.
Body composition was determined by Echo-MRI (Echo Medical Sys-
tems, Houston, TX, USA) and oxygen consumption (VO2), respiratory
exchange ratios (RER) were monitored by indirect calorimetry using the
comprehensive laboratory animal monitoring system (CLAMS; Co-
lumbus Instruments, Columbus, OH, USA). EE was estimated using VO2
and VCO2 values from indirect calorimetry, using the following equa-
tion: EE (in kJ/h)¼ (15.818 VO2)þ (5.176 VCO2) [7]. Food intake
and activity (horizontal (XD) and vertical (Z)) was also monitored using
the CLAMS during a 24 h period. Daily voluntary activity was measured
by providing a running wheel to the mice and monitoring the running
distance. Grip tests, treadmill and cold tests were performed as pre-
viously described in Ref. [8]. Maximal running speed and VO2 were
evaluated using a calorimetric treadmill (Columbus instruments, Co-
lumbus, OH, USA) with an incremental speed protocol. During the run,
VO2 and VCO2 were measured. The experiment was stopped when
mice showed obvious signs of exhaustion. Glucose and insulin toler-
ance was analyzed by measuring blood glucose following intraperi-
toneal injection of 2 g/kg glucose or 0.3 U insulin/kg (human insulin
actrapid, Lilly), respectively, after a 12 h fast. For HFD-fed mice, the
insulin dose was increased to 0.75 U/Kg. Unless otherwise speciﬁed,
animals were sacriﬁced at 8 a.m. after a 12 h fast, in order to stabilize
systemic parameters and to allow the measurement of blood
biochemistry in the fasting state. Blood samples were collected in
EDTA-coated tubes and plasma was isolated after centrifugation.
Plasma insulin was determined in plasma samples using speciﬁc
ELISA kits (Merck Millipore, Darmstadt, Germany). All other plasma
parameters were measured using Dimension Xpand Plus (Siemens
Healthcare Diagnostics AG, Dudingen, Suisse). Tissues were collected
upon sacriﬁce and ﬂash-frozen in liquid nitrogen.
2.3. Hyperinsulinemic-euglycemic clamp
Hyperinsulinemic-euglycemic clamps were performed at Phyiogenex
(Physiogenex SAS, France) according to standardized procedures,
following the Guide for the Care and Use of Laboratory animals and
French laws. Mice (n ¼ 12 per genotype) underwent a surgery pro-
cedure to insert a catheter in the femoral vein. Clamp was performed
ﬁve days post-surgery on 6 h fasted mice. Following a ﬁrst blood
collection, mice received a bolus of D-[3-3H] glucose and then
radiotracer (30 mCi/min/kg) infusion started for up to 210 min. Insulin
was simultaneously infused at 4 mU/kg/min for the ﬁrst 100 min and atMOLECULAR METABOLISM 4 (2015) 118e131  2014 The Authors. Published by Elsevier GmbH. This is an open access article u
www.molecularmetabolism.com12 mU/kg/min for the last 110 min. Glucose infusion rate was adjusted
according to blood glucose levels until the two respective euglycemic
steadystates were reached. Moreover, 1 h before the end of the clamp,
a bolus injection of 14C-2Deoxy-Glucose was performed. At the end of
the 210-minute perfusion, mice were euthanized, several tissues were
collected and 14C-radioactivity was measured to determine glucose
utilization in epididymal and sub-cutaneous WAT, brown adipose tis-
sue, vastus lateralis skeletal muscle and liver.
2.4. Respirometry studies
Respirometry studies in homogenates from freshly extracted BAT and
liver or in permeabilized EDL muscle were performed using high-
resolution respirometry (Oroboros Oxygraph-2k; Oroboros In-
struments, Innsbruck, Austria), as described previously in Ref. [9] with
minor modiﬁcations. All respirometry experiments were performed on
fresh tissues immediately following dissection. Liver and BAT were
homogenized (mechanical permeabilization) in amino acid-depleted
respirometry medium (0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lacto-
bionate, 10 mM KH2PO4, 20 mM HEPES, and 110 mM sucrose, pH 7.1)
and the equivalent of 2 mg wet tissue was added to the experimental
chamber. Glycolytic EDL skeletal muscle was placed in relaxing buffer
(in mM: 2.8 Ca2K2EGTA, 7.2 K2EGTA, 5.8 ATP, 6.6 MgCl2, 20 taurine,
15 Na2 phosphocreatine, 20 imidazole, 0.5 dithiothreitol, and 50 MES,
pH 7.1) immediately after dissection, and ﬁbers were gently separated.
Following sarcolemmal permeabilization in relaxing buffer supple-
mented with 0.005% (wt/vol) saponin, the tissue was equilibrated in
respirometry medium [in mM: 0.5 EGTA, 3 MgCl2, 60 K-lactobionate,
20 taurine, 10 KH2PO4, 20 HEPES, 110 sucrose and 0.1% (wt/vol)
bovine serum albumin, pH 7.1]. Thereafter, skeletal muscle ﬁbers were
blotted forw30 s to remove the excess of medium and 1.0e2.5 mg of
tissue was added to each chamber. All the tissues were assessed in
respirometry medium. Oxygen ﬂux (denoted as “Leak” in ﬁgures) was
measured by adding malate (ﬁnal concentration 2 mM), pyruvate
(10 mM) and glutamate (20 mM) in the absence of ADP. Complex I-
driven oxidative phosphorylation (denoted as “C I” in ﬁgures) was
quantiﬁed by the addition of ADP (5 mM; 0.5 mM for tests in BAT). This
was followed by the addition of succinate (10 mM) for convergent
electron ﬂow through both complex I and II (denoted as “C I þ II” in
ﬁgures). Subsequently, carbonylcyanide-4-(triﬂuoromethoxy)-phenyl-
hydrazone (FCCP) was titrated to achieve maximum ﬂux through the
electron transfer system (denoted as “ETS” in ﬁgures). Finally, electron
transport through complex I (denoted as “ETS C II” in ﬁgures) and III
was inhibited by the sequential addition of rotenone (0.1 mM) and
antimycin A (2.5 mM), respectively. The remaining O2 ﬂux after inhi-
bition with Antimycin A (O2 ﬂux independent of the ETS) was sub-
tracted from the values of each of the previous steps. O2 ﬂux values are
expressed relative to tissue wet weight per second.
2.5. Western blotting
Cells were lysed in lysis buffer (50 mM TriseHCL pH7.5, 150 mM NaCl,
EDTA 5 mM, NP40 1%, sodium butyrate 1 mM, protease inhibitors).
Proteins were quantiﬁed using BCA assay (Pierce). For western blot-
ting, proteins were separated by SDS-PAGE and transferred onto
nitrocellulose membranes. Antibodies are listed in Supplemental
Table 1. All spliced together non-contiguous lanes from the same
gels are marked using a thin black line and noted in the ﬁgure. The
images for the full, unedited gels are available upon request.
2.6. Determination of mitochondrial vs. nuclear DNA ratio
Total genomic DNA was extracted from liver, skeletal muscle
(gastrocnemius) and brown adipose tissue using a DNeasy Blood andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 119
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Mitochondrial and nuclear DNA (COX2 and HK2, respectively) were
measured by quantitative PCR using SYBR Green. Primers are listed in
Supplemental Table 2.
2.7. RNA extraction and qPCR
Total mRNA from all studied tissues was extracted according to the
instructions provided by the manufacturer, using TRIZOL (Life technol-
ogies). The mRNA concentration was measured using a Nanodrop 1000
(Thermo Scientiﬁc, Wilmington, MA). Conversion to cDNA was per-
formed using SuperScript II (Life technologies) with oligo (dT2), Random
Hexamers primers and RNAsine (Roche) according to the protocol
provided by the manufacturer. Quantiﬁcation of mRNA expression was
performed using the SYBR Green real time PCR technology (Roche).
Reactions were performed in duplicate in a 384-well plate using the
Light Cycler (Roche). Primers are listed in Supplemental Table 2. Gene
expression was normalized with b2-microglobulin and cyclophillin as
housekeeping genes. Relative gene expression between genotypes was
assessed through the DDCt method [10].
2.8. Microarray
Illumina microarrays were used to proﬁle the gene expression levels of
approximately 25,000 genes, in the BAT of WT and SIRT1Tg/Tg mice
(n¼ 6 per group). The mRNA samples were hybridized on a single chip
and raw microarray data were analyzed using the Illumina genome
studio software. The results of the microarray are available in the GEO
database with the accession number GSE62324. To test for sets of
related genes that might be systematically altered in SIRT1Tg/Tg BAT,
we used a Gene Set Enrichment Analysis (GSEA), a method which
combines information from the members of previously deﬁned sets of
genes (e.g. curated biological pathways) to increase signal relative to
noise and improve statistical power to detect subtle changes [11].
Complete details on the method for this analysis are available on the
http://www.broad.mit.edu/gsea website. Brieﬂy, genes from the
microarray were ﬁrst ranked according to the expression difference
(signal to noise ratio) between genotypes. The extent of association
was then measured by a non-parametric running sum statistic termed
the enrichment score (ES), and the maximum ES (MES) was recorded
over each gene set. Permutation tests were used to assess the sta-
tistical signiﬁcance of the MES, which is calculated as the fraction of
the 100 random permutations of the gene list in which the top pathway
gave a stronger result than that observed in the actual data. The un-
adjusted nominal P value estimates the statistical signiﬁcance of a
gene set without adjusting for gene set size or multiple hypothesis
testing, whereas the false discovery rate (FDR) statistic adjusts for
both. In this analysis, an FDR of approximately 30% was considered
acceptable. The nominal P-values for the gene set are indicated in the
corresponding panels.
2.9. Citrate synthase activity
Citrate synthase activity was performed on tissue accordingly to the
protocol of Sigma’s Citrate Synthase Assay Kit (CS0720).
2.10. Triglycerides and glycogen content
Triglycerides and Glycogen content were performed on tissue
accordingly to the protocol of Bioassay System Assay Kit (ETGA-200
and E2GN-100, respectively).
2.11. Lipolysis
Lipolysis was determined on freshly extracted tissues using the ZenBio
assay kit (LIP-3-NC), incubating the tissues in assay buffer supplemented120 MOLECULAR METABOLISM 4 (2015) 118e131  2014 The Authors. Published bywith a vehicle or with isoproterenol 1 mM during 5 h at 37 C under
agitation and then glycerol release were measured.
2.12. Cell culture
Primary brown adipocytes cells were obtained from the interscapular
BAT of WT or SIRT1 transgenic mice and immortalized as previously
described in Ref. [12]. Immortalized brown pre-adipocytes were grown
in “growth medium” (GM) (DMEM supplemented with 10% FBS, 20 nM
Insulin, and 1.5 nM 3,30,5 Triiodothyronine (T3)). For differentiation,
cells were growth until 90% conﬂuence with GM and next stimulated
during 36 h with “differentiation medium” (GM supplemented of
0.5 mM dexamethasone, 1 mM rosiglitazone, 0.125 mM indomethacin
and 0.5 mM isobutylmethylxanthine (IBMX)). Then, cells were culti-
vated in GM until ﬁnal differentiation (day 6 of differentiation). Adipo-
cytes are fully differentiated when they exhibited multilocular lipid
droplets in their cytoplasm. For experiments, norepinephrine (A0937,
SIGMA) or CL316,243 (C5976, SIGMA) were added to GM at 1 mM
concentrations unless otherwise speciﬁed.
2.13. Statistical analyses
Statistical analyses were performed with Prism software (GraphPad).
Differences between two groups were analyzed using Student’s t test
(two-tailed), and multiple comparisons were analyzed by ANOVA with a
Bonferroni post hoc test. A P-value less than 0.05 was considered
signiﬁcant. Data are expressed as means  SEM.
3. RESULTS
3.1. SIRT1Tg/Tg mice display higher energy expenditure and
glucose tolerance
SIRT1Tg/Tg mice displayed a moderate SIRT1 overexpression in skeletal
muscle, liver, white adipose tissue (WAT) and BAT, both at the mRNA
and protein levels (Figure 1A,B). In contrast to the heterozygous mice,
where changes were reported to be 2e4-fold [4], up to 10-fold in-
creases in SIRT1 expression were observed in the WAT from SIRT1Tg/Tg
mice. When fed an LFD, SIRT1Tg/Tg mice displayed a similar body
weight (Figure 1C) and composition (Figure 1D) as WT mice. However,
SIRT1Tg/Tg showed a marked increase in O2 consumption and EE both
during the light and the dark phases (Figure 1E and Figure S1A-B). The
respiratory exchange ratio (RER) of SIRT1Tg/Tg mice was lower than in
WT mice during the light phase, indicating a higher use of lipid energy
substrates (Figure 1F and Figure S1C). The bigger amplitude in RER
changes between the light and dark phases (Figure 1F) suggests an
enhanced ﬂexibility to shift between carbohydrate and lipid energy
sources. While food intake was similar between genotypes (Figure 1G),
the CLAMS analysis revealed a clear tendency to decreased activity in
SIRT1Tg/Tg mice (Figure S1D). The lower spontaneous activity of
SIRT1Tg/Tg mice was more evident when daily voluntary activity was
analyzed in regular housing cages (Figure 1H). This is an interesting
aspect, as SIRT1Tg/- mice also showed a tendency towards lower
activity on LFD [4], and this decrease was largely signiﬁcant in the
SirBACO mice [5]. Also, the treatment with STACs has been reported to
decrease spontaneous activity in mice [8,13]. Hence, systemic SIRT1
activation might reduce spontaneous activity, which could explain why
SIRT1Tg/Tg mice have a similar body weight despite higher EE.
We next evaluated if the marked differences of SIRT1Tg/Tg mice on en-
ergy homeostasis could have an impact on glucose metabolism. Blood
glucose and insulin levels were similar between WT and SIRT1Tg/Tg
mice, either in the fed or fasted state (Table 1). SIRT1Tg/Tg mice, how-
ever, displayed a higher glucose tolerance (Figure 2A) and response to
insulin (Figure 2B), based on intraperitoneal glucose and insulinElsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Evaluation of energy homeostasis in SIRT1Tg/Tgmice. (A, B) 20week-oldwild-type (WT) and SIRT1Tg/Tg (Tg)micewere sacriﬁced tomeasure (A) themRNA and (B) protein levels
of SIRT1 in the indicated tissues. (C, D) Three months old WT and Tg mice were fed ad libitum with a low fat diet and (C) body weight and (D) body composition were measured through
EchoMRI. (E) Oxygen consumption (VO2) and (F) Respiratory exchange ratio (RER) were measured by indirect calorimetry using a comprehensive laboratory animal monitoring system
(CLAMS). (G) Food intake ameasured during the indirect calorimetry tests. (H) Voluntary wheel running activity wasmeasured in 20-week-oldWT and Tgmice. All values are presented as
mean SEM of n¼ 10e14 mice for each genotype. *indicates statistical signiﬁcant difference between WT (white bars and circles) and Tg mice (black bars and circles) at P< 0.05.tolerance tests, respectively. In order to evaluate the key tissues
contributing to the higher glucose tolerance and insulin response, we
performed a hyperinsulinemic-euglycemic clamp onWT and SIRT1Tg/Tg.
Both phenotypes required similar glucose infusion rates (GIR) at lowTable 1 e Blood biochemistry.
Parameters WT (n ¼ 6) Tg (n ¼ 6)
Glycemia (mg/dL) e Fed 150.63  3.12 155.14  6.01
Glycemia (mg/dL) e Fasted 75.67  4.8 81.14  5.1
Insulinemia (ng/mL) e Fed 2.73  0.34 2.74  0.30
Insulinemia (ng/mL) e Fasted 1.10  0.21 1.05  0.10
Triglycerides (mmol/L) 1.08  0.13 1.50  0.19
Free Fatty Acid (mmol/L) 0.63  0.11 0.75  0.09
Total Cholesterol (mmol/L) 2.8  0.2 2.8  0.2
HDL-Cholesterol (mmol/L) 2.78  0.15 2.74  0.25
LDL-Cholesterol (mmol/L) 0.11  0.03 0.09  0.02
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levels were raised to asses peripheral glucose uptake (12 mU/kg/min),
SIRT1Tg/Tg mice required a signiﬁcantly higher GIR (Figure 2C). In these
conditions, insulin equally decreased hepatic glucose production in both
genotypes (Figure 2D), illustrating that differences in hepatic function do
not account for the higher GIR rate. Glucose disposal rates were also
calculated for individual tissues in response to the insulin challenges.
Glucose uptakewas similar between genotypes in skeletal muscle, liver,
epididymal and sub-cutaneous WAT (Figure 2E). In contrast, BAT
glucose uptake was higher in SIRT1Tg/Tg mice (Figure 2E) suggesting
that BAT is the main responsible for the higher GIR required to maintain
euglycemia in SIRT1Tg/Tg mice.
These observations contrast with those in SIRT1Tg/ mice, where
higher glucose tolerance was only observed on HFD [4,5]. In this
sense, SIRT1Tg/Tg mice also displayed a strong protection
against glucose intolerance (Figure S2A) and insulin resistancender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 121
Figure 2: SIRT1 overexpression improves insulin sensitivity through higher BAT glucose uptake. (A) An intraperitoneal glucose tolerance test and (B) an introperitoneal insulin
tolerance test were performed on 4-month-old WT and Tg mice. Area under the curve (AUC) or area above the curve (AAC) calculations are present on the top right of each glucose
excursion. (CeE) Hyperinsulinemic-euglycemic clamp was performed on WT and SIRT1Tg/Tg mice fed on low fat diet. Glucose Infusion Rate (GIR) measured at two different levels of
insulin infusion (4 and 12 mU/kg/min) (C), glucose ﬂuxes (D) and Glucose uptake in different tissues (inguinal sub-cutaneous and epididymal WAT, BAT, vastus lateralis skeletal
muscle and liver) (E) are represented. All values are presented as mean  SEM of n ¼ 12e14 mice for each genotype. * indicates statistical signiﬁcant difference between WT
(white bars and circles) and Tg mice (black bars and circles) at P < 0.05.
Original article(Figure S2B) on HFD, despite a similar body weight gain as WT
mice (Figure S2C).
3.2. Skeletal muscle and liver are not affected in SIRT1Tg/Tg mice
on low fat diet
The fact that SIRT1Tg/Tg mice did not display higher insulin sensitivity in
skeletal muscle is in line with recent reports using transgenic models
with even higher SIRT1 overexpression [14,15]. However, these results
do not rule out other possible contributions of SIRT1 transgenesis to
muscle metabolic properties. In this sense, mitochondrial biogenesis
and higher oxidative capacity are believed to be two key metabolic
actions triggered by SIRT1 in skeletal muscle [16]. To further explore
these areas, we ﬁrst, submitted the mice to grip and treadmill tests in122 MOLECULAR METABOLISM 4 (2015) 118e131  2014 The Authors. Published byorder to evaluate muscle force and endurance, respectively. However,
none of them were improved by SIRT1 transgenesis (Figure 3A,B). In
line with this, no differences in maximal running speed or maximal VO2
could be found between genotypes (Figure S3A-B). No structural or
oxidative proﬁle differences were observed between the gastrocne-
mius muscles of WT and SIRT1Tg/Tg mice, based on succinate dehy-
drogenase stainings (data not shown). WT and SIRT1Tg/Tg mice also
showed no differences when evaluating mitochondrial vs. nuclear DNA
ratios (Figure 3C), citrate synthase (CS) activity (Figure 3D) or the levels
of mitochondrial-related mRNAs and proteins in gastrocnemius muscle
(Figure 3E,F). The protein content of mitochondrial respiratory complex
subunits was also unaffected in highly oxidative (soleus) or glycolytic
(EDL) muscles (Figure S3C). Interestingly, an upregulation of severalElsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: Muscle function is not affected by SIRT1 transgenesis. (A) Muscle force was evaluated in wild type (WT) and SIRT1Tg/Tg (Tg) mice through a grip test. (B) Running
distance was evaluated by submitting mice to an endurance treadmill test. (C) Mitochondrial DNA content in gastrocnemius muscle was measured and normalized to nuclear DNA
copy number. (D) Citrate synthase activity was measured in quadriceps muscle. (E) Total mRNA was extracted from gastrocnemius muscles and used for qPCR analysis of the
markers indicated. (F) Protein analysis of mitochondrial markers in total homogenates of quadriceps muscle (thin black lines on gels are used for lanes that were run on the same
gel but were non-contiguous). (G) Oxidative phosphorylation and electron transfer system capacity in permeabilitzed EDL muscle ﬁbers of WT and Tg mice. All values are presented
as mean  SEM of n ¼ 8e10 mice for each genotype. * indicates statistical signiﬁcant difference between WT (white bars and circles) and Tg mice (black bars and circles) at
P < 0.05.transcriptional regulators, such as the peroxisome proliferator-
activated receptor-a (PPARa) and the Forkhead O box (FOXO) 1 and
3a, was observed in SIRT1Tg/Tg muscles. However, the above results
suggest that these changes were not enough to affect muscle
endurance and mitochondrial function. To further substantiate the lack
of differences in mitochondrial function between WT and SIRT1Tg/Tg
mice, we performed respirometry analyses in permeabilized EDL
muscle ﬁbers. Uncoupled respiration (leak) through complex I, stim-
ulated with malate, pyruvate and glutamate, was not affected by SIRT1
transgenesis (Figure 3G). Similarly, maximal respiration in the coupled
state, with electron input through complex I alone (C I) or through
complex I þ II e after the addition of succinate e (C I þ II) wasMOLECULAR METABOLISM 4 (2015) 118e131  2014 The Authors. Published by Elsevier GmbH. This is an open access article u
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port system (ETS) capacity was also similar, even after the addition of
the complex I inhibitor rotenone (ETS CII) (Figure 3G). Hence, no major
differences in mitochondrial function could be observed in the skeletal
muscle from WT and SIRT1Tg/Tg mice.
Next, we also examine the consequences of SIRT1 transgenesis in liver
tissue on LFD. While the hyperinsulinemic-euglycemic clamp revealed
no major effects of SIRT1 transgenesis in liver glucose turnover on LFD
(Figure 2D,E), the liver accounts for the beneﬁts of SIRT1 transgenesis
on glucose metabolism upon HFD [4,5]. To further evaluate hepatic
glucose metabolism in our SIRT1Tg/Tg mice on LFD diet, we challenged
the mice with a pyruvate tolerance test. After the injection of pyruvate, ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 123
Original articlegluconeogenic precursor, glucose excursions were comparable be-
tween WT and SIRT1Tg/Tg mice (Figure 4A). We also failed to detect
differences between the two genotypes on histological Oil red’O stain-
ings (Figure 4B) or at the level of hepatic triglyceride or glycogen content
(Figure 4C,D). As inmuscle, no changes could be found onmitochondrial
DNA content (Figure 4E), on CS activity (Figure 4F) or at the mRNA and
protein level of several mitochondrial components (Figure 4G,H). In line
with the comparable response to pyruvate, the expression of key glu-
coneogenic genes, such as glucose 6-phosphatase (G6Pase) and
phopho-enol-pyruvate carboxylase (PEPCK), was similar between ge-
notypes (Figure 4G). As in muscle, some transcriptional regulators ofFigure 4: Hepatic function is not critically affected by SIRT1 transgenesis. (A) Blood gluco
after an overnight fast (bar ¼ 600 mm) (C, D) Hepatic triglyceride (C) and glycogen (D) cont
and normalized to nuclear DNA copy number. (F) Citrate synthase activity in liver. (G) Tot
Protein analysis of mitochondrial markers in total liver homogenates (thin black lines on
Oxidative phosphorylation and electron transfer system capacity in liver homogenates of W
genotype. * indicates statistical signiﬁcant difference between WT (white bars and circles
124 MOLECULAR METABOLISM 4 (2015) 118e131  2014 The Authors. Published bylipid metabolism were upregulated, including PPARa, FOXO1 and
FOXO3a (Figure 4G). Interestingly, respirometry analyses revealed a
higher complex II activity in SIRT1Tg/Tg livers (Figure 4I). However, based
on the absence of differences in hepatic metabolism upon pyruvate and
insulin challenges, the physiological relevance of these increases is
unclear.
3.3. Brown adipose function is improved in SIRT1 transgenic mice
The lack of effects on WAT insulin response in SIRT1Tg/Tg mice on LFD
(Figure 2E) was in line with the absence of differences in the weight of
different WAT depots (Figure S4A) or their histological aspectse curves after a pyruvate (2 g/kg) challenge. (B) Oil Red’O staining in WT and Tg livers
ent was measured after an overnight fast. (E) Mitochondrial DNA content was measured
al liver mRNA was extracted and used for qPCR analysis of the markers indicated. (H)
gels are used for lanes that were run on the same gel but were non-contiguous). (I)
T and Tg mice. All values are presented as mean  SEM of n ¼ 8e10 mice for each
) and Tg mice (black bars and circles) at P < 0.05.
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(Figure S4B). Accordingly, we found no alterations in mitochondrial
function (Figure S4C) or lipolytic capacity (Figure S4D) in the WAT of
SIRT1Tg/Tg mice.
Finally, we focused on the BAT function in SIRT1Tg/Tg mice, as it is the
tissue most likely explaining the differences in glucose homeostasis
between genotype (Figure 2E). Strikingly, the color of the BAT from
SIRT1Tg/Tg mice was more intense (Figure 5A), likely due to a lower
accumulation of lipids, as reﬂected in the much smaller lipid droplets
observed through hematoxylin/eosin staining (Figure 5B). We next
evaluated BAT thermogenic function by placing the mice at 6 C and
monitoring body temperature for 5 h. While no signiﬁcant differences on
the basal state, SIRT1Tg/Tg mice maintained better their body temper-
ature during the cold challenge (Figure 5C), suggesting a higher ther-
mogenic activity. As in other tissues, we found no differences betweenFigure 5: Brown adipose function is improved in SIRT1 transgenic mice. (A) Pictures of br
the BAT of wild type (WT) and SIRT1Tg/Tg (Tg) mice (bar ¼ 600 mm) (C) Brown adipose
Mitochondrial DNA content in BAT from WT and Tg mice, normalized to nuclear DNA copy
BAT from WT and Tg mice (thin black lines on gels are used for lanes that were run o
expression proﬁles of BAT from WT and Tg mice. (G) Total mRNA was extracted from BAT
capacity in BAT. (I) Citrate synthase activity in BAT from WT and Tg mice. (J) Lipolysis was
WT and Tg BAT using the acetylation status of RelA(p65) and FOXO1 as readout. All valu
statistical signiﬁcant difference between WT (white bars and circles) and Tg mice (black
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content of respiratory complexes subunits at protein and mRNA levels
(Figure 5E and Figure S5A, respectively). To infer the possible mech-
anisms by which SIRT1Tg/Tg mice displayed altered BAT function, we
performed microarray analyses (results available in the GEO database
with the accession number GSE62324). Geneset enrichment revealed a
strongly signiﬁcant (nominal P-value< 0.01) increase of genes related
to fatty acid metabolism and, more in particular, lipid catabolism
(Figure 5F and Figure S5B). The microarray results were validated by
quantitative real-time PCR (qPCR), which conﬁrmed that genes related
to b-oxidation were strongly induced in the BAT of SIRT1Tg/Tg mice
(Figure 5G). This way, key genes for lipid oxidation, such as the long-
chain acyl-CoA dehydrogenase (LCAD), the medium-chain acyl-CoA
dehydrogenase (MCAD) or the carnitine palmitoyltransferase 1bown adipose tissue (BAT) from WT and Tg mice. (B) Hematoxylin and eosin stainings on
thermogenic function was evaluated by placing WT and Tg mice at 6 C for 5 h. (D)
number. (E) Western Blots were performed to evaluate the protein levels of proteins in
n the same gel but were non-contiguous). (F) Gene set enrichment analyses of gene
and used for qPCR analysis. (H) Oxidative phosphorylation and electron transfer system
evaluated by measuring glycerol release in isolated BAT. (K) SIRT1 activity was tested in
es are presented as mean  SEM of n ¼ 8e10 mice for each genotype. * indicates
bars and circles) at P < 0.05.
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Original article(CPT1b), were signiﬁcantly elevated in SIRT1Tg/Tg mice (Figure 5G). This
was, again, in line with an upregulation of PPARa and FOXOs. Inter-
estingly, the protein and mRNA levels of the uncoupling protein UCP1
were also elevated in SIRT1Tg/Tg BAT (Figure 5E and G, respectively).
The key role of UCP1 in energy dissipation could explain the higher EE
(Figure 5E,F) and thermogenic potential (Figure 5C) observed in
SIRT1Tg/Tg mice. In line with this, respirometry analyses revealed an
almost 2-fold increase in uncoupled respiration (leak) in the BAT from
SIRT1Tg/Tg mice, and a higher maximal ETS capacity (Figure 5H).
Concordantly, CS activity was also increased (Figure 5I). Finally, we
examined the lipolytic rates in WT and SIRT1Tg/Tg BATs. The results
obtained illustrate how the basal lipolytic rates in the BAT from SIRT1Tg/
Tg arew20% higher than those of their control WT mice (Figure 5J).
This result is in line with the higher basal phosphorylation of the hor-
mone sensitive lipase (HSL) observed in protein homogenates
(Figure 5E), and could explain the lower lipid accumulation observed
through histology (Figure 5B). Also, the mRNA level of the type II
iodothyronine deiodinase (DIO2) was also increased in the BAT of
SIRT1Tg/Tg mice, supporting a higher catabolic rate (Figure 5G). Alto-
gether, these data suggest that SIRT1Tg/Tg mice have a higher ther-
mogenic function and lipid oxidation-related gene expression in BAT.
While SIRT1 activation has been classically linked to enhanced mito-
chondrial biogenesis [1] mitochondrial content was not affected in the
BAT from SIRT1Tg/Tg mice, despite a markedly higher SIRT1 activity, as
testiﬁed by the reduced acetylation of NFkB and FoxO1 (Figure 5K).
3.4. SIRT1 transgenesis affects BAT response to adrenergic
stimulation
We next aimed to understand whether the changes in BAT biology
elicited by SIRT1 transgenesis were derived from alterations in the BAT
differentiation process or on its function. For this purpose, we
immortalized primary brown pre-adipocytes from WT and SIRT1
transgenic mice. SIRT1 transgenesis did not affect the cellular
morphology (Figure 6A), lipid droplet accumulation (Figure S6A) and TG
content (Figure 6B) of the cultured brown adipocytes. Brown adipocyte
differentiation markers, such as Prdm16, Cidea and PPARg, were
similarly induced at the mRNA and protein level after differentiation
between the two genotypes (Figure 6C,D). In line with this, the mRNA
expression of these markers in adult BAT from WT and SIRT1Tg/Tg mice
was also similar (Figure 6G). These analyses also conﬁrmed that SIRT1
overexpression levels in undifferentiated and differentiated transgenic
immortalized brown adipocytes are comparable to those in the SIRT1
transgenic BAT (Figures 1A,B and 6D). Hence, SIRT1 overexpression
does not affect brown adipocyte differentiation. Strikingly, while Ucp1
expression, both at the mRNA and protein level, increased upon dif-
ferentiation of WT brown adipocytes, it did much less in the brown
adipocytes from SIRT1 transgenic mice (Figure 6D,E). A recent pub-
lication indicated that SIRT1 can amplify the transcriptional response to
PKA signaling [17]. We hence reasoned that the increased UCP1 levels
observed in SIRT1Tg/Tg BAT could be consequent to a higher response
of SIRT1 transgenic adipocytes to b3-adrenergic stimulation. To test
this hypothesis, we analyzed the response of differentiated brown
adipocytes to adrenergic stimulation using norepinephrine (NE) or the
synthetic agonist CL316,243 (CL). Both agents induced a comparable
increase in p-HSL after 5 h of treatment (Figure 6F). This indicates that
early signaling responses to b3 stimulation are not altered by SIRT1
transgenesis. However, the transcriptional response of Ucp1 to NE or
CL was dramatically enhanced in SIRT1 brown adipocytes (Figure 6F,G
and Figure S6B). The enhanced transcriptional response to b3 agonists
in SIRT1 transgenic adipocytes was certiﬁed using another adrenergic
target in the BAT, the PPARg coactivator 1a (PGC-1a) [17]126 MOLECULAR METABOLISM 4 (2015) 118e131  2014 The Authors. Published by(Figure S6C). The transcriptional responsiveness of SIRT1 transgenic
adipocytes to adrenergic stimulation was higher at concentrations as
low as 10 nM, as testiﬁed by Ucp1 mRNA analyses (Figure 6G).
Similarly, SIRT1 transgenic brown adipocytes achieved maximal Ucp1
transcriptional response to adrenergic stimulation at earlier time-
periods than WT adipocytes (Figure 6H). Thus, our results indicate
that SIRT1 grants brown adipocytes with a higher transcriptional
responsiveness to b3 agonists.
3.5. Thermoneutrality blunts the differences in glucose
homeostasis of SIRT1Tg/Tg mice
The results above illustrate that, upon adrenergic stimulation, SIRT1
transgenic adipocytes have an exacerbated transcriptional response
(Figure 6G,H) that allows them to recover UCP1 protein levels to
comparable levels of that of WT mice even within a few hours
(Figure 6F). We reasoned that if this stimulation had a chronic char-
acter, this could lead to even further increases and explain the higher
activity of BAT in SIRT1Tg/Tg mice. In this sense, it must be taken into
account that at regular housing conditions (w20e22 C), mice are
below thermoneutrality, which leads to a basal stimulation of the BAT
thermogenic function. Considering the above results, this chronic basal
adrenergic tone could be responsible for the higher BAT function, Ucp1
expression and EE observed in SIRT1Tg/Tg mice. To test this hypothesis,
we housed WT and SIRT1Tg/Tg mice at thermoneutrality (30 C), which
blunts thermogenic activity [18]. In turn, this would allow us to evaluate
whether the enhancement of BAT function is responsible for the higher
glucose tolerance and insulin sensitivity of SIRT1Tg/Tg mice on LFD.
After one month at thermoneutrality, SIRT1Tg/Tg and WT mice were
undistinguishable at the level of body weight (Figure 7A), body
composition (Figure 7B) and food intake (Figure S7A). As in normal
housing conditions the total activity of the SIRT1Tg/Tg mice was also
reduced at thermoneutrality (Figure S7C). Importantly, however,
thermoneutrality blunted the effect of SIRT1 transgenesis on VO2
(Figure 7C), EE (Figure S7B) and RER (Figure S7D) that we previously
observed in normal housing conditions (Figure 1E,F). In addition,
thermoneutrality also abrogated the higher glucose tolerance and in-
sulin sensitivity of SIRT1Tg/Tg mice (Figure 7D,E). Interestingly, a higher
glycemia was clearly observed in SIRT1Tg/Tg mice 15 min after a
glucose load (Figure 7D), even though the physiological relevance of
this difference is unclear. These evidences, together with the results
obtained during hyperinsuilnemic-euglycemic clamp (Figure 2E),
clearly demonstrate that enhanced BAT function is the primordial event
by which SIRT1Tg/Tg mice are granted better glucose homeostasis in
regular housing conditions. Thermoneutrality increased the lipid
droplet size in the BAT of both WT and SIRT1Tg/Tg mice (Figures 5B and
7F), and rendered both genotypes histologically undistinguishable.
Similarly, the higher basal expression of lipid oxidation-related genes
observed in SIRT1Tg/Tg mice was blunted on thermoneutral conditions
(Figure 7G). Interestingly, we observed a dramatic reduction in Ucp1
expression in the BAT of SIRT1Tg/Tg compared to that of WT mice
(Figure 7G), which is very reminiscent of the lower Ucp1 mRNA levels
observed in cultured primary brown adipocytes. This substantiates that
the higher Ucp1 levels in mice housed at normal conditions are
consequent to an exacerbated response to a basal adrenergic tone. As
expected, thermoneutrality lowered uncoupled respiration (leak) in
both WT and SIRT1Tg/Tg mice (Figures 5H and 7H). While similar
respiratory proﬁles were observed in the BAT from WT and SIRT1Tg/Tg
mice on thermoneutrality, we noted a tendency to a lower respiratory
leak in SIRT1Tg/Tg mice (Figure 7H), in line with the decrease in Ucp1
expression. Interestingly, thermoneutrality did not affect the higher
Complex II activity in the livers of SIRT1Tg/Tg mice (Figures 4H and 7H).Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 6: SIRT1 transgenic adipocytes display an exhacerbated response to b3-adrenergic stimulation. Brown pre-adipocytes from wild-type (WT) and SIRT1 transgenic (Tg) mice
were isolated and immortalized. (A) The morphology of immortalized brown adipocytes was evaluated before (day 0) and after (day 6) differentiation. (B) Total triglyceride content in
differentiated brown adipocytes was evaluated. (C) Total mRNA levels were extracted from pre-adipocytes and differentiated adipocytes and used for qPCR analysis. (D) Total
protein extracts were used to evaluate diverse differentiation markers in differentiated and undifferentiated adipocytes. (E) Ucp1 expression was measured in total mRNA extracts of
differentiated brown adipocytes. (F) Differentiated WT and Tg adipocytes were stimulated with 1 mM of norepinephrine (NE) or 1 mM of CL316,243 (CL) during 5 h at 37 C. Then,
total proteins were extracted and used for western blot analysis. (G) WT and Tg brown adipocytes were treated with CL in a doseeresponse fashion for 5 h at 37 C and then total
mRNA was extracted to measure Ucp1 expression. (H) WT and Tg brown adipocytes were treated with 1 mM CL and incubated at 37 C. Then, total mRNA was extracted at the
times indicated to measure Ucp1 expression. All values are presented as mean  SEM of at least n ¼ 4 independent experiments, each of them run in triplicate. * indicates
statistical signiﬁcant difference between WT (white bars and circles) and Tg mice (black bars and circles) at P < 0.05.On one side, this testiﬁes for the BAT-speciﬁc impact of the inter-
vention. On the other, it argues that the increase in Complex II activity
in the liver is not responsible for the better glucose tolerance of
SIRT1Tg/Tg mice on regular housing conditions. Finally, we evaluated
whether thermoneutrality also blunted the higher lipolytic rates we
observed in SIRT1Tg/Tg mice on non-thermoneutral conditions
(Figure 5J). As expected, thermoneutral conditions decreased lipolytic
rates in WT mice, as noticed when comparing the values obtained in
Figure 5J (white bar; 2.80  0.25 mmol/(mg of tissue*h)) and at
thermoneutral conditions (Figure 7I, white bar, 1.51 0.22 mmol/(mg
of tissue*h)). Thermoneutrality also blunted the higher lipolytic ratesMOLECULAR METABOLISM 4 (2015) 118e131  2014 The Authors. Published by Elsevier GmbH. This is an open access article u
www.molecularmetabolism.comand HSL phosphorylation in the BAT from SIRT1Tg/Tg mice and made
them undistinguishable from WT mice (Figure 7I).
4. DISCUSSION
While SIRT1 activation has been linked to diverse metabolic health
beneﬁts, the key tissue(s) responsible for such actions remain elusive.
Mouse models with a moderate SIRT1 overexpression have shown a
key protective role for SIRT1 on liver function upon HFD [4,5]. Here we
describe how the expression of just one additional copy of SIRT1 to
that of previous works [4,19], is sufﬁcient to enhance BAT activity,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 127
Figure 7: Thermoneutrality blunts the insulin-sensitizing effect of SIRT1 transgenesis. Three months old WT and Tg mice were fed ad libitum with low fat diet and placed at
thermoneutrality (30 C) for one month before phenotyping. Then, (A) Body weight and (B) body composition were measured using Echo-MRI. (C) O2 consumption was evaluated
using a comprehensive animal laboratory monitoring system; (D) An intraperitoneal glucose tolerance test and (E) an insulin tolerance test were performed on 4 months old mice.
(F) Hematoxylin and eosin stainings of BAT from WT and Tg mice (bar ¼ 600 mm). (G) Total mRNA was extracted from BAT and used for qPCR analysis. (H) Oxidative phos-
phorylation and electron transfer system capacity in BAT (top) and liver (bottom) of WT and Tg mice. (I) Lipolysis rates were evaluated by measuring glycerol release from BAT. At
the bottom HSL and p-HSL levels were evaluated in total BAT protein extracts. All values are presented as mean  SEM of n ¼ 12 mice for each genotype. * indicates statistical
signiﬁcant difference between WT (white bars and circles) and Tg mice (black bars and circles) at P < 0.05.
Original articleleading to increased EE and improved glucose homeostasis even on
LFD.
SIRT1 transgenesis did not affect BAT differentiation, yet it dramatically
enhanced BAT transcriptional responses to b3-adrenergic stimulation.
Hence, the chronic adrenergic tone taking place in mice housed below
thermoneutrality drives a higher basal BAT function in SIRT1Tg/Tg mice.
In agreement with our results, the SirBACO model has an exacerbated
transcriptional response of thermogenic genes after an acute cold
exposure [17]. In this case the authors proposed a mechanism in
which PKA activation led to the phosphorylation of a residue in the
catalytic domain of SIRT1, Ser434, which led to an increase in intrinsic
SIRT1 enzymatic activity [17] in the absence of changes in NADþ
levels. In line with this, we did not observe changes in the BAT NADþ
levels between WT and SIRT1Tg/Tg mice (Figure S5C). Further efforts
from the Accili lab have demonstrated how SIRT1 ampliﬁes the128 MOLECULAR METABOLISM 4 (2015) 118e131  2014 The Authors. Published bybrowning response of WAT in response to cold stimuli [20]. Altogether,
these works and ours certify the ability of SIRT1 to amplify the
response to b3-adrenergic stimuli. Strikingly, the SirBACO model did
not display a basal BAT phenotype [5,17]. Our results on thermo-
neutrality, however, indicate that small differences in the adrenergic
tone can even drive to opposite outcomes of SIRT1 on thermogenic
gene expression. This way, SIRT1 transgenesis led to a lower Ucp1
expression in primary brown adipocytes and in BAT from animals at
thermoneutral conditions. The repressive action of SIRT1 on Ucp1 is in
line with the role of SIRT1 as an energy sensor triggering adaptations
aimed to optimize energy production [1]. Accordingly, SIRT1 represses
Ucp2 expression in pancreatic b-cells [21,22]. The ability of SIRT1 to
shift from a corepressing to a coactivating function on thermogenic
gene sets might be determined by environmental cues enhancing, in
this case, PKA signaling. In this sense, SIRT1 has also been describedElsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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as both a positive and negative regulator of PGC-1a and, hence,
mitochondrial biogenesis [23,24]. In fact, the simultaneous activation
of AMPK signaling is key to determine the outcomes of SIRT1 action on
PGC-1a activity and mitochondrial gene expression [25]. In this sense,
we did not observe changes in AMPK activity in our SIRT1Tg/Tg model,
which might explain the lack of impact on mitochondrial gene
expression (Figure S5D). This highlights how small differences in
environmental conditions can critically inﬂuence SIRT1 actions, which
might have strong implications not only for the evaluation of transgenic
mouse models, but also for genetic association studies in humans.
Interestingly, higher EE and glucose tolerance were also observed in
the ﬁrst generated model of SIRT1 moderate overexpression [26]. A
particularity of that model was a high expression of the transgene in
WAT and BAT, but not in the liver or skeletal muscle [26]. More
recently, it has been shown that the deletion of SIRT1 in adipose tis-
sues is enough to drive body weight gain and metabolic dysfunction in
mice [27]. Conversely, the selective overexpression of SIRT1 in the
adipose tissues enhances EE and prevents age-related insulin resis-
tance [28]. Our results reﬁne all these studies by establishing SIRT1
action in the BAT as the key determinant of whole body thermogenic
function, EE and glucose homeostasis. Importantly, the higher SIRT1
content did not manifest into an overt phenotype in liver or muscle.
Likely, the activity of SIRT1 needs to be triggered by either hormonal or
nutritional inputs. In liver, this might only take place upon HFD, when
liver phenotypes are clearly observed in SIRT1 transgenic mice [4,5].
The lack of phenotype in skeletal muscle is not entirely surprising, as
mice with much higher SIRT1 overexpression in muscle also fail to
display any overt alteration [14,15]. Thus, endogenous SIRT1 levels
might be able to account for all the necessary SIRT1 activity required to
trigger metabolic adaptations in this tissue. Our results also contrast
with the largely accepted notion that SIRT1 is a master regulator of
mitochondrial biogenesis. In agreement with previous observations [4],
the protein or mRNA levels of mitochondrial respiratory complexes
were unaffected in SIRT1Tg/Tg tissues. This, does not rule out, however,
that SIRT1 overexpression at a higher (>100-fold), non-physiological,
level can impact mitochondrial gene expression [14,29].
While SIRT1 can potentially impact on multiple transcriptional pro-
grams, lipid oxidation-related gene sets were the most signiﬁcantly
upregulated in the BAT from SIRT1Tg/Tg mice. In fact, SIRT1 trans-
genesis increased PPARa, FOXO1 and FOXO3a expression in all tis-
sues examined, certifying an intimate link between SIRT1 and these
transcriptional regulators in the control of lipid catabolism. Previous
reports have demonstrated the ability of SIRT1 to interact with PPARa
and enhance its transcriptional activity on lipid catabolism-related
genes [30,31]. In this model, SIRT1 would enhance PPARa activity
by deacetylating PGC-1a in the PPARa transcriptional complex
[30,31]. Conversely, SIRT1 deletion leads to a dramatic decrease in the
expression of PPARa target genes, at least in liver [30]. FOXOs are
directly deacetylated by SIRT1, an action that targets FOXO activity
onto speciﬁc gene sets, including oxidative stress genes [32]. Knock-in
mice expressing a FOXO1 form mimicking constitutive deacetylation
displayed a marked use of lipid as energy source and enhanced
lipolytic response to isoproterenol [33], in line with our ﬁndings.
However, the potent effect of FOXO1 deacetylation on gluconeogenic
gene expression [33] is not manifested in our SIRT1Tg/Tg mice. This
would conﬁrm that, despite similar overexpression levels in both tis-
sues, SIRT1 transgenesis has a deeper impact in the BAT than in liver,
at least on LFD. PPARa and FOXOs, in addition, might also constitute
key mediators of the action of SIRT1 on Ucp1 expression, as both
directly regulate the Ucp1 promoter in brown fat cells [12,34].MOLECULAR METABOLISM 4 (2015) 118e131  2014 The Authors. Published by Elsevier GmbH. This is an open access article u
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insulin-stimulated glucose uptake in the BAT? One possibility is that
higher lipolytic rates and prevention of fat deposition (Figure 5J and B,
respectively) might spare the BAT from the accumulation of lipid
species that could potentially interfere with insulin signaling, such as
ceramides or diacylglycerols (DAGs) [35]. While excessive lipolysis in
the WAT can be detrimental for whole body insulin sensitivity [36], this
is generally associated with a lipid overﬂow onto other tissues. In
contrast, the higher lipolytic ﬂux in the BAT of SIRT1Tg/Tg mice is fully
met by an increase in mitochondrial fatty acid oxidation capacity and
uncoupling activity. In skeletal muscle, HSL activity seems to be a
critical determinant of insulin sensitivity, as it can prevent ATGL-driven
accumulation of DAGs and the consequent disruption of insulin
signaling [37]. In this sense, the higher HSL activity in the BAT of
SIRT1Tg/Tg mice might act in a similar fashion. In HFD, lower inﬂam-
mation was a key mechanism by which SIRT1Tg/- mice retained he-
patic insulin sensitivity [9]. Interestingly, in our microarrays, cytokine
and inﬂammatory pathways were two of the most signiﬁcantly
downregulated gene-sets in the BAT of SIRT1Tg/Tg mice (Figure S5B),
suggesting that a lower baseline inﬂammation state might also
contribute to its higher insulin sensitivity. Recently, using a BAT
transplantation model, it has been shown that increasing BAT function
promotes an increase in FGF21 and IL-6 expression, which could act in
an endocrine fashion to alter insulin sensitivity in other peripheral
tissues [38]. This, however, is not the case in our model, as enhanced
insulin sensitivity is not manifested in muscle or eWAT (Figure 2E).
Accordingly, we failed to detect differences in BAT FGF21 or IL-6
expression between genotypes (data not shown).
A ﬁnal aspect for discussion is whether SIRT1 activation via trans-
genesis is comparable to that achieved via improving NADþ avail-
ability. In theory, at similar NADþ levels, SIRT1 activity will increase
directly in line with increases in expression, unless SIRT1 over-
expression decreases NADþ content via excessive consumption. This
is not the case in the BAT of SIRT1Tg/Tg mice, where SIRT1 activity is
higher, based on the evaluation of NFkB and FOXO1 acetylation
(Figure 5K), without affecting NADþ levels (Figure S5C). Hence, SIRT1
transgenesis should ensure a linear increase in SIRT1 activity with the
level of overexpression, at least up to a certain threshold. The efﬁcacy
of NADþ boosting strategies on SIRT1 activity, however, depends on
whether intracellular NADþ levels are rate-limiting for SIRT1 activity in
the basal state. Dietary supplementation with the NADþ precursor
nicotinamide riboside (NR) leads to SIRT1 activation in the BAT [39].
This suggests that basal NADþ levels are rate-limiting for SIRT1 ac-
tivity in the BAT. However, a NADþ precursor will fail to activate SIRT1
if NADþ is not rate-limiting or in tissues with limited capacity to
metabolize the precursor into NADþ. In the case of NR, additionally, it
also leads to the activation of other sirtuins, such as SIRT3, by
increasing NADþ content in the mitochondrial compartment [39,40].
Therefore the comparison between transgenic and NADþ-related
SIRT1 gain-of-function models should be taken carefully. In the case of
STACs, resveratrol and SRT1720 have major effects on BAT activity
[8,13]. However, STACs have also marked effects in skeletal muscle
oxidative capacity and prevent body weight gain on HFD [8,13]. None
of these effects have been observed in this or previous studies using
models of moderate SIRT1 overexpression [4,5]. Therefore, either
STACs increase SIRT1 activity in muscle in a much more stronger
fashion than the above mentioned SIRT1 gain-of-function mouse
models, or some effects might be inﬂuenced by off-target actions on
other molecular paths regulating energy metabolism, as discussed
recently in Ref. [1].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 129
Original articleAltogether, this manuscript describes a key physiological role of SIRT1
in BAT biology and establishes SIRT1 as a sensitive gauge for the
adrenergic response of the BAT, a property that could be exploited for
therapeutic approaches aimed to ameliorate glycemic control.
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